
OmicVision is a biotech startup pioneering single-cell spatial proteomics to transform precision medicine. Their technology platform, Deep Visual Proteomics (DVP), combines high-resolution microscopy, deep-learning based cell classification and segmentation, laser microdissection, and ultra-sensitive mass spectrometry to quantify thousands of proteins with single-cell precision. This enables unbiased spatial proteomics, creating detailed proteomic maps for enhanced understanding of cellular states and disease. OmicVision's platform supports the entire drug development spectrum, including biomarker identification, patient stratification for clinical trials, and indication expansion for existing therapeutics. Founded by Dr. Andreas Mund and Dr. Maximilian Strauss, the company is based in Copenhagen and aims to radically improve patient care by unlocking the next generation of precision medicine.

OmicVision is a biotech startup pioneering single-cell spatial proteomics to transform precision medicine. Their technology platform, Deep Visual Proteomics (DVP), combines high-resolution microscopy, deep-learning based cell classification and segmentation, laser microdissection, and ultra-sensitive mass spectrometry to quantify thousands of proteins with single-cell precision. This enables unbiased spatial proteomics, creating detailed proteomic maps for enhanced understanding of cellular states and disease. OmicVision's platform supports the entire drug development spectrum, including biomarker identification, patient stratification for clinical trials, and indication expansion for existing therapeutics. Founded by Dr. Andreas Mund and Dr. Maximilian Strauss, the company is based in Copenhagen and aims to radically improve patient care by unlocking the next generation of precision medicine.